
July 21 (Reuters) - Autolus Therapeutics PLC 6A3Ay.F:
AUTOLUS THERAPEUTICS’ CAR T THERAPY AUCATZYL® (OBECABTAGENE AUTOLEUCEL) GRANTED EUROPEAN MARKETING AUTHORIZATION FOR ADULT PATIENTS (AGE 26 AND OLDER) WITH RELAPSED OR REFRACTORY B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (R/R B-ALL)
Further company coverage: [6A3Ay.F]